

# tag2007

## PROGRESS IN THE FIGHT FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR AIDS

DEAR FRIENDS OF TAG,

It is a privilege to work with some of the world's smartest, most dedicated, and highly accomplished AIDS activists. It is equally a privilege to be working with an amazing and committed board of directors and with TAG's incredible family and friends. I'm writing to share with you

**"Activists have awakened the entire world to the suffering of people living with HIV and fundamentally altered the way we view science. . . ."**

our accomplishments in 2007. You made them happen. And I am writing to urge you to continue and expand your support for the Treatment Action Group in 2008 and beyond.

In December 2007 at our annual Research in Action Award (RIAA)

ceremony, Harvard University researcher and RIAA recipient Dr. Jim Yong Kim made some remarks about TAG's work that I wanted to share with you. "AIDS activism has changed our society indelibly. Activists have awakened the entire world to the suffering of people living with HIV and fundamentally altered the way we view science, drug development, and even sexuality."

I couldn't have said it better myself. Given the urgency of the AIDS epidemic and the unmet needs and demands AIDS research is facing while many people with HIV still need lifelong services, better treatment, and, ultimately, a cure, I am asking you to step up your support for the Treatment Action Group and its important work. Thanks for all you've given, and for giving more.

**Barbara Hughes**  
President, Board of Directors

### WHAT'S INSIDE

- TAG At a Glance 2007
- TAG Programs
- TAG Limited Edition 2007
- 2007 Contributors
- The Palm Donor Circle
- 2007 Financials



**New York City Council Speaker Christine Quinn (center) receives the Research in Action award from executive director Mark Harrington and TAG board president Barbara Hughes.**

## Research in Action Awards 2007

Treatment Action Group's 2007 Research in Action Awards (RIAA) honored public health leader Dr. Jim Yong Kim, New York City Council Speaker Christine C. Quinn, and gay rights activist David Mixner.

TAG's 2007 Research in Action Awards, held at the Drawing Center in New York City on December 9, 2007, honored three individuals who have made significant contributions to AIDS research and activism. "We are honoring three tireless workers who fight AIDS through public health, public service, and social activism," said Mark Harrington, executive director of TAG.

### **Dr. Jim Yong Kim**

Jim Yong Kim, MD, PhD, is the Director of the Francois-Xavier Bagnoud Center for Health and Human Rights at the Harvard School of Public Health, as well as a professor at Harvard Medical School and Chair of the Harvard Medical School Department of Social Medicine. The focus of the Center under Dr. Kim's leadership is HIV/AIDS—especially

efforts to achieve universal access to HIV prevention, treatment, and care. He is the former director of the World Health Organization's HIV/AIDS Department. Dr. Kim is the recipient of a 2003 MacArthur "Genius" Award, and in 2006 was selected as one of *Time* magazine's 100 most influential people.

#### The Honorable Christine C. Quinn

As the first woman, openly gay, and Irish Speaker of the New York City Council, Christine Quinn brings a new perspective to the diverse challenges facing each of New York City's distinct communities. One of the fiercest advocates for the creation, preservation, and improvement of New York City's HIV/AIDS Services Administration, Speaker Quinn has been a longtime pioneer for equal rights and comprehensive health care. She has been rated one of the 50 most powerful women in New York City by the *New York Post*, and one of the most influential New Yorkers by *New York Magazine*.

#### David Mixner

Once named by *Newsweek* as the most powerful gay man in America, David Mixner has been a highly regarded leader in American politics and international human rights for over 40 years. Mr. Mixner is an author of books and screenplays, as well as having written for various influential publications. David Mixner has for decades been an unofficial advisor to elected officials and business leaders on domestic and foreign policy.

The benefit was hosted by commediene Jackie Hoffman. Artist Carrie Yamaoka donated a limited-edition series of artworks that were displayed during the evening. The event raised over \$100,000 to support TAG's work.

## 2007 AT A GLANCE

### JANUARY

**January 2007:** TAG starts the first year of its four-year **TB/HIV Advocacy Project**, supported by the **Bill & Melinda Gates Foundation**. TAG makes a presentation at a New York workshop on TB research and development sponsored by **Médecins sans Frontières (MSF)**.

### FEBRUARY

TAG staff participate in the annual **Retrovirus** Conference in **Los Angeles**. TAG hires its new TB/HIV coordinator **Claire Wingfield**, MPH, an experienced AIDS advocate with previous experience at the **National AIDS Treatment Advocacy Project** and the **Asian Pacific Islander Wellness Center**. TAG's Executive Director **Mark Harrington** is profiled in *Nature Medicine* [*Nature Medicine* 13, 270] and gives a talk on TB research funding needs at the **North American TB Union** meeting in **Vancouver, B.C.**

### MARCH

TAG's **Mark Harrington**, TB/HIV Project Director **Javid Syed**, and **Claire Wingfield** visit tuberculosis and HIV research sites and community activist organizations in **Uganda** and **South Africa**. TAG's HCV/HIV Project Director **Tracy Swan** organizes and speaks at the international workshop on research and access to **experimental drugs for hepatitis C virus (HCV)** for HCV/HIV coinfecting persons in Sitges, Spain; this results in a manifesto for coinfection trials known as the **Sitges Statement**. **Mark Harrington** and **Javid Syed** attend the **Keystone TB Pathogenesis Symposium** in Vancouver, B.C.

### APRIL

**Mark Harrington** participates in a workshop on the second generation of **anti-HIV treatment research trials** in **Jinja, Uganda**. In New York, TAG cosponsors a workshop on **HIV pre-exposure prophylaxis (PrEP)** research.

### MAY

**Mark Harrington** testifies on the need for expanded research to combat **multi- and extensively drug-resistant (M/XDR) tuberculosis** at the National Institute of Allergy and Infectious Disease **Advisory Council** meeting. TAG sponsors a workshop on **research activism** in **Rio de Janeiro, Brazil**, and sponsors the first **community advocacy group** meeting of the Centers for Disease Control and Prevention (CDC)-funded **Tuberculosis Trials Consortium (TBTC)**.


### JUNE

Britain's prestigious medical journal *The Lancet* publishes an article cowritten by **Mark Harrington** on the need for expanded efforts to **detect smear-negative and extrapulmonary TB** among people with HIV [*Lancet*; 369:2042-2049]. TAG organizes an activist workshop in **Cape Town, South Africa** and sponsors a meeting of global TB/HIV activists with the **World Health Organization's Stop TB Department**, the **Stop TB Partnership**, and the **Foundation for Innovative New Diagnostics** in **Geneva, Switzerland**. TAG forms a partnership with the **International Community of Women Living with HIV/East Africa (ICW/East Africa)** to collaborate on TB/HIV activism.

1.



2.



3.



1. Research in Action Award recipient Dr. Jim Yong Kim discusses health policy with TAG TB/HIV staffers Javid Syed and Claire Wingfield.
2. The Drawing Center, site of the 2007 RIAA.
3. TAG supporters Jim Gilday and Ernie Thomas at RIAA.

**Tracy Swan** participates in the **HAART Oversight Committee** meeting in **London**, where she advocates for **better postmarketing research** on anti-HIV drugs.

## JULY

TAG board member **Robert Pini** arranges a premiere screening of the movie *Hairspray!* for TAG's donors in **New York**. TAG publishes *The 2007 Pipeline Report: Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis* by **Mark Harrington**, **Bob Huff**, and **Richard Jefferys** at the **Fourth International AIDS Society Conference** on HIV pathogenesis, prevention, and treatment in **Sydney, Australia**.

## AUGUST

TAG publishes HCV/HIV Project Director **Tracy Swan's Guide to Hepatitis C for People Living with HIV: Testing, Coinfection, Treatment, and Support**. The **U.S. Food and Drug Administration** (FDA) approves Pfizer's CCR5 receptor blocker **maraviroc** (U.S. brand name **Selzentry**), the first new drug in its class.

## SEPTEMBER

Senior Public Health Fellow at the Council on Foreign Relations **Laurie Garrett**—whose journalism has won the most prestigious awards in the field, the **Peabody**, the **Polk**, and the **Pulitzer**—holds an event in her Brooklyn Heights apartment for TAG's **Michael Palm Major Donor Circle**.

Thank you, Laurie! TAG sponsors an African TB/HIV activist workshop in **Kampala, Uganda**. TAG's research and policy newsletter *TAGline* covers a range of issues, including rapidly progressing hepatitis C in New York City gay men; the Sitges Statement on HCV Drug Development; a review of FDA hearings on HCV drug development; the changing patterns of antiretroviral treatment usage; suggestions for improving TB drug susceptibility testing; an overview of how basic research is a government responsibility; and a view of new directions in HIV research. The **National Institutes of Health** (NIH) stops the phase IIB study of Merck's **Adenovirus-5 (Ad5) HIV vaccine** candidate due to an excess of new HIV infections among the vaccinated. Throughout the fall TAG's **Richard Jefferys** provides vital coverage of the emerging story.

## OCTOBER

**Sue Perez**, MPH, joins TAG as our first **Federal Policy Director**, establishing TAG's presence in **Washington, DC**. Sue's previous experience includes work in **Côte d'Ivoire** in the **Peace Corps** and work on **tuberculosis advocacy** at the RESULTS Educational Fund in Washington, DC. The FDA approves Merck's HIV integrase inhibitor **raltegravir** (brand name **Isentress**), the first in its class. TAG's **Tracy Swan** serves as ad-hoc community representative to the FDA **Antiviral Drugs Advisory Committee**, which recommends approval for the drug.

## NOVEMBER

TAG sponsors the **Treatment Action Group** and **Stop TB Partnership**

Satellite Workshop on **MDR- and XDR-TB in the Context of HIV Infection** in **Cape Town, South Africa**, just prior to the **37th Union World Conference on Lung Disease**. Later the same week TAG staff join the **AIDS Law Project/AIDS Rights Alliance of Southern Africa/Treatment Action Campaign's** march for TB research, prevention, and treatment. TAG publishes the second annual *Tuberculosis Research and Development: A Critical Analysis of Funding Trends, 2005-2006*. The **Public Library of Science Medicine** (*PloS Medicine*) publishes an article cowritten by **Mark Harrington** on the need for controlled clinical trials for **MDR-TB** [*PloS Med* 4(11): e292]. TAG is awarded a prestigious three-year grant from the **John M. Lloyd Foundation** for excellence in AIDS advocacy. **Richard Jefferys** posts extensive interviews with HIV pathogenesis researchers **Steve Deeks** and **Douglas Nixon**.

## DECEMBER

TAG's **Mark Harrington** and **Richard Jefferys** attend the **Third International Workshop on HIV Persistence and Latency** and plan a 2008 workshop to focus efforts on an **HIV cure**. TAG's 2007 **Research in Action Awards** event honors New York City Council Speaker **Christine Quinn**, Harvard physician-activist and researcher **Dr. Jim Yong Kim**—previously the director of the **World Health Organization's** HIV Department during the **"3x5"** initiative—and AIDS and gay/lesbian rights activist **David Mixner**.

4.



4. Working group at TAG's TB/HIV activist training in Uganda, September 2007.

5.



5, 6. Marching for TB research in Cape Town, November 2007.

6.



7.



7. RIAA honorees Christine Quinn and Dr. Jim Yong Kim with TAG executive director Mark Harrington and board president Barbara Hughes.



# TAG PROGRAMS

## The Antiretroviral Project

The Treatment Action Group's Antiretroviral Project closely monitors and influences the state of research on anti-HIV drug discovery, development, dissemination, and postmarketing surveillance; advocates for accelerated, better-focused efforts in this area; and focuses on innovative treatments for drug-resistant HIV that are easier to take, less toxic, and/or represent a major therapeutic breakthrough. TAG advocates for better postmarketing research on approved antiretroviral drugs to improve standards of care; works on domestic and international treatment guidelines; and educates and mobilizes policymakers, researchers, and the HIV community on anti-HIV treatment research. TAG works with academic researchers, clinicians, federal agencies such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), and with domestic and international community coalitions to achieve these ends.

## The Michael Palm HIV Pathogenesis and Prevention Project

The Treatment Action Group's Palm Project works to improve the state of basic research on HIV/AIDS, including pathogenesis, immunology, vaccine, microbicide, and preclinical discovery and development. The Project advocates for better and faster research into the pathogenesis of HIV infection and the interactions between HIV and the immune system, for research on immune-based therapeutic approaches to HIV infection, for accelerated, scientifically rigorous HIV vaccine and microbicide research, and on projects to educate and mobilize policymakers, researchers, and the HIV community on basic science and vaccine development.

## The Hepatitis/HIV Project

The Treatment Action Group's Hepatitis/HIV Project works to improve the state of research on the opportunistic complications, infections, cancers, and coinfections related to HIV/AIDS and coinfections with viral hepatitis diseases such as hepatitis B and C. TAG advocates for greater efforts in this area while working to educate and mobilize policymakers, researchers, and the HIV community. In 2007, TAG's efforts focused on hepatitis C virus (HCV) infection, which coinfects up to a quarter of all people with HIV in the United States and often leads to end-stage liver disease. TAG works to improve research, treatment, and community awareness of these coinfections.

## The TB/HIV Advocacy Project

TAG's TB/HIV Advocacy Project educates and empowers communities affected by HIV/AIDS domestically and internationally to understand, mobilize, and respond effectively to the challenges posed by the intersecting epidemics of tuberculosis (TB) and HIV. Worldwide, TB is the leading opportunistic infection and a leading cause of death among people living with HIV. To educate, mobilize, and empower HIV communities, TAG works to increase community understanding of TB/HIV coinfection and to increase the quality and quantity of research, treatment, and resources to combat the two epidemics.

## U.S. and Global Community Education and Mobilization

TAG educates communities around the U.S. and throughout the world affected by HIV about the latest developments in research,

prevention, and treatment. TAG also trains and mentors leaders of HIV/AIDS organizations and networks to strengthen their advocacy and scientific literacy. TAG staff work with individuals and organizations in the U.S. and around the world to catalyze more effective global interventions against the HIV pandemic and to strengthen treatment education and literacy efforts in developing countries.

## TAG Limited Edition 2007 CARRIE YAMAOKA

Roberta Smith of the *New York Times* has called artist Carrie Yamaoka's work "a rejuvenation of minimalism, spurred by new materials, more refined techniques and fresh ideas."

Carrie generously donated a limited edition of 20 works, each unique, which were offered via sponsorships of \$3,500 and above for TAG's 2007 Research in Action Awards. A limited number are still available. You can view images and purchase the work on TAG's website, [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org).

Carrie is a New York-based artist and a dedicated supporter of TAG who works in a zone between painting and sculpture. She has exhibited widely in the U.S. and internationally, including at Artists Space, the Wexner Center, Mass MOCA, and the Albright-Knox Gallery.



8.



9.

8. Steve Barrows, Martin Blair, Robert Pini  
9. Dr. Jim Yong Kim receives his RIAA.  
10. Attendees examine the RIAA program with cover art by Carrie Yamaoka.

10.



## CONTRIBUTORS 2007

### \$100,000 OR MORE

The Bill & Melinda Gates Foundation  
The Michael Palm Foundation

### \$50,000—\$99,000

John M. Lloyd Foundation  
Merck & Co.  
Newman's Own Foundation  
Schering-Plough Corporation

### \$50,000—\$49,999

Boehringer Ingelheim Pharmaceuticals, Inc.  
Bristol-Myers Squibb  
Gilead Sciences, Inc.  
Pfizer, Inc.  
Roche and Trimeris/Hoffmann-LaRoche Inc.  
Tibotec Therapeutics  
World Health Organization

### \$10,000—\$24,999

Broadway Cares/Equity Fights AIDS  
David Corkery  
Richard A. & Barbara Knowles Debs/  
The Debs Foundation  
Gesso Foundation  
GlaxoSmithKline  
Richard M. Lynn & Joseph Evall

### \$5,000—\$9,999

Nicholas A.R. Debs/Debs & Co.  
Pfizer Foundation  
The Mary Wohlford Foundation

### \$2,500—\$4,999

Timothy & Mary C. Casey  
Randall G. Drain  
Marcus Edward & Ken O'Neill  
Fuse  
M. Lee Garrison  
James M. Goldrick  
Dr. Mathilde Krim/  
Mathilde & Arthur B. Krim Foundation  
Michael K. Longacre  
Alby P. Maccarone, Jr.  
Stephen Mack & Robert Monteleone  
Mark O'Donnell & James E. McGreevey  
Jason I. Osher & Richard R. Schubel  
Andrew David Zacks/  
The Zacks Family Foundation

### \$1,000—\$2,499

Arcus Foundation  
Jeffrey Arnstein & Michael Field  
Katherine C. & Thomas M. Ash, III  
Michael A. Becker & Tee Scatuorchio  
David Bohnett Foundation  
Michael Cowing  
Constance D'Aurizio  
Diamond Information Center

Steven & Judith O. Gluckstern/  
The Lucky Star Foundation  
David Gold  
Richard & Judith Harrington  
Gregory H. Hoffman & Bradford Jones  
David Hollander & Robert Shaw  
Barbara F. Hughes & Andrea B. Dailey  
Paul E. Kennedy & John Marsh  
Bonnie McEwan & Kathleen P. Duncan/  
Make Waves  
Robert Pini & Michael Boodro  
Dr. Allan & Clare Rosenfield  
James Saakvitne  
David Saylor & Charles Kreloff  
Dr. Bruce R. Schackman & Edward K. Sikov  
Nina Schwalbe & Sally Girvin/  
Nina Schwalbe Fund of Tides Foundation  
Evan Schwartz & Robert Fitterman  
Marvin Shulman  
John A. Silberman, Esq. & Elliot Carlen  
Monte Steinman

### \$500—\$999

Benjamin, Christine & Darius Anagnos  
Dr. Judith D. Auerbach & Jim Robinson  
Robert Bank & Allen Cohen/GMHC  
Claudio S. Barbosa  
In Honor of Alby Maccarone  
Eli & Jalile Camhi  
Erika B. Dailey  
Edward J. Davis & Thomas D. Phillips  
Joy Episalla & Carrie Yamaoka  
Hartly Fleischmann  
Sebastian J. Florio  
Steven M. Frank & Dr. Elizabeth S. Powell  
Andre Gregory & Cindy Kleine  
Mark Harrington  
James C. Hormel  
Bob Huff  
James Huniford  
The Dorothy Loudon Foundation  
Carey C. Maloney & Hermes Mallea  
Barry A. Margolin  
Loring R. McAlpin  
Drs. Mike McCune & Karen K. Smith-McCune  
H. Tollie Miller  
Kenneth T. Monteiro & Leo J. Blackman  
George J. & Mirla Morrison  
Annalee Newman Fund of New York  
Community Trust  
James F. O'Sullivan/  
John A. Hartford Foundation  
John & Patricia Pollok  
Walter Rieman  
In Memory of Tom Stoddard  
Daniel C. Schaffer  
Peter A. Schamel  
Jane Silver  
United Way  
Mitchell Warren/AVAC  
William J. Zwart & David W. Berchenbriter

### \$250—\$499

Peter L. Allen  
Dr. Gregory W. Bartha  
Daniel J. Bellm & Yoel H. Kahn  
Michael A. Benevento & Adam B. Gottlieb  
Marc J. Berman & John Yakubik  
Martin Blair & Steve Barrows  
Richard M. Buxbaum & Catherine B. Hartshorn  
Dr. & Mrs. Charles C.J. Carpenter  
Jeanie Carstensen  
Paula & Mitchell Chalfin/Neshoma Network  
Dr. Gene Copello & Frederick Wright/  
The AIDS Institute  
Denise B. Dailey  
Scott Dainton  
Dinowitz & Bove CPAs  
Edward Dullea & Phillip B. Miller  
Alan E. Farley  
Carol H. & John L. Field/  
Fidelity Charitable Gift Fund  
William C. Gibson & Lou Cohen  
Leslie Asako Gladsjo  
Ronald J. Goldberg & Joe Chiplock  
Barry Goralnick & Keith D. Gordon  
Christopher Harrington & Daphne Powell  
Craig Hempstead  
Marc Juris  
Edward J. Kennedy  
Nancy & Joel Kremsdorf  
F. Joseph McConnell & Erik Haagenzen  
Laura A. Morrison  
Donna M. Pauldine  
In Memory of Jeff Palladino  
Leslie Fay Pomerantz  
Candis L. & Daniel S. Ramelli, III  
Virun Rampersad  
Lousine Shamamian/Arev Productions  
Jeffrey P. Sholeen  
David Sigal & Brad Hoylman  
Grail Walsh Sipes  
In Memory of Carl Parisi  
Peter R. Staley  
Margie & Mort Steinberg  
Paul A. Teixeira & David A. Rimple  
Daniel Tietz/ACRIA  
Dr. Keith S. Tobin  
Matthew D. Warnecke  
P. Forrest Williams  
Drs. Bret I.W. Zbar & Lori Goldman Zbar  
In Honor of Laurie Garrett

Special thanks to all who have  
so generously helped the  
Treatment Action Group in  
its efforts in 2007 to fight for  
better treatment, a vaccine,  
and a cure for AIDS.

---

# Palm Donor Circle

## Special Recognition by TAG

---

The Palm Donor Circle of the Treatment Action Group is TAG's major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951-1998). Members of the Palm Donor Circle made individual donations of \$1,000 or more to TAG in 2007.

---

Jeffrey Arnstein & Michael Field  
Katherine C. & Thomas M. Ash III  
Michael A. Becker & Tee Scatuorchio  
Timothy & Mary C. Casey  
David Corkery  
Michael Cowing  
Constance D'Aurizio  
Richard A. & Barbara Knowles Debs  
Nicholas A. R. Debs  
Randall G. Drain  
Marcus Edward & Ken O'Neill  
Joy Episalla & Carrie Yamaoka  
M. Lee Garrison  
Steven & Judith O. Gluckstern  
David Gold  
James M. Goldrick  
Richard & Judith Harrington  
Gregory H. Hoffman & Bradford Jones  
David Hollander & Robert Shaw  
Barbara F. Hughes & Andrea B. Dailey  
Paul E. Kennedy & John Marsh

Dr. Mathilde Krim  
Michael K. Longacre  
Richard M. Lynn & Joseph Evall  
Alby P. Maccarone, Jr.  
Stephen Mack & Robert Monteleone  
Bonnie McEwan & Kathleen P. Duncan  
Mark O'Donnell & James E. McGreevey  
Jason I. Osher & Richard R. Schubel  
Robert Pini & Michael Boodro  
Dr. Allan & Clare Rosenfield  
James Saakvitne  
David Saylor & Charles Kreloff  
Dr. Bruce R. Schackman &  
Edward K. Sikov  
Nina Schwalbe & Sally Girvin  
Evan Schwartz & Robert Fitterman  
Marvin Shulman  
John A. Silberman, Esq., & Elliot Carlen  
Monte Steinman  
W. Kirk Wallace & Mark M. Sexton  
Andrew David Zacks

---

## TAG BE INVOLVED

### About TAG

Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

Program areas include antiretroviral treatments, basic science, vaccines, prevention, hepatitis, and tuberculosis.

### Join TAG's Board

TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG board president, to learn more about board opportunities with TAG.

212 253 7922

[barbara.hughes@treatmentactiongroup.org](mailto:barbara.hughes@treatmentactiongroup.org)

### Contribute!

TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

To make a charitable donation to TAG, call 212 253 7922 or go online to [www.treatmentactiongroup.org](http://www.treatmentactiongroup.org).

#### BOARD OF DIRECTORS

**PRESIDENT**  
Barbara Hughes

**SECRETARY &  
TREASURER**  
Laura Morrison

Joy Episalla  
Kevin Goetz  
Gregory Hoffman, Esq.  
Richard Lynn, Ph.D.  
Alby P. Maccarone, Jr.  
Mark O'Donnell  
Jason Osher  
Robert Pini  
David Sigal  
Monte Steinman

**EXECUTIVE DIRECTOR**  
Mark Harrington

**ANTIRETROVIRAL PROJECT  
DIRECTOR**  
Bob Huff

**MICHAEL PALM PROJECT  
COORDINATOR**  
Richard Jefferys

**HEPATITIS/HIV PROJECT  
DIRECTOR**  
Tracy Swan  
**COORDINATOR**  
Lei Chou

**TB/HIV PROJECT  
DIRECTOR**  
Javid Syed, MPH  
**COORDINATOR**  
Claire Wingfield, MPH

**FEDERAL POLICY DIRECTOR**  
Sue Perez, MPH

**ADMINISTRATOR**  
Joseph McConnell

**Treatment Action Group**  
611 Broadway, Suite 308  
New York, NY 10012  
Tel 212 253 7922, Fax 212 253 7923  
[tag@treatmentactiongroup.org](mailto:tag@treatmentactiongroup.org)  
[www.treatmentactiongroup.org](http://www.treatmentactiongroup.org)

TAG is a nonprofit, tax-exempt 501(c)(3) organization. E.I.N. 13-3624785

**TAG**  
Treatment Action Group

# TAG FINANCIALS 2007

## STATEMENTS OF FINANCIAL POSITON

### Assets

#### Current assets:

Cash and cash equivalents	\$ 651,189	\$ 378,806
Contributions receivable	1,986,400	1,406,171
Prepaid expenses and other receivables	99,606	1,895

#### TOTAL CURRENT ASSETS

**2,737,195** **1,786,872**

Property and equipment—net of accumulated depreciation	43,739	7,356
Security deposits	20,654	4,455

#### TOTAL ASSETS

**\$ 2,801,588** **\$ 1,798,683**

### Liabilities and Net Assets

#### Current liabilities

Accounts payable and accrued expenses	\$ 7,054	\$ 4,441
---------------------------------------	----------	----------

#### TOTAL LIABILITIES

**7,054** **4,441**

#### Net assets

Unrestricted	718,134	367,238
Temporarily restricted	2,076,400	1,427,004

#### TOTAL NET ASSETS

**2,794,534** **1,794,242**

#### TOTAL LIABILITIES AND NET ASSETS

**\$ 2,801,588** **\$ 1,798,683**

### Statement of Cash Flows

#### Cash flows from operating activities:

Increase (Decrease) in net assets	\$ 1,000,292	\$ 1,090,940
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Depreciation	6,387	4,301

#### (Increase) Decrease in current assets:

Contributions receivable	(580,229)	(1,335,546)
Prepaid expenses and other receivables	(97,711)	964
Security deposits	(16,198)	-

#### (Decrease) Increase in current liabilities:

Accounts payable and accrued expenses	2,613	(911)
---------------------------------------	-------	-------

#### NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES

**\$ 315,154** **\$ (240,252)**

#### Cash flows from investing activities:

Purchases of property and equipment	(42,771)	(3,051)
Net cash used in investing activities	(42,771)	(3,051)
Net decrease (increase) in cash balance	272,383	(243,303)

CASH, BEGINNING OF YEAR	378,806	622,109
-------------------------	---------	---------

#### CASH, END OF YEAR

**\$ 651,189** **\$ 378,806**

# TAG FINANCIALS 2007

## STATEMENTS OF ACTIVITIES

	Unrestricted	Temporarily Restricted	Year ended December 31	
			2007	2006
<b>Revenue and support:</b>				
Direct mail	\$ 36,108	\$ -	\$ 36,108	\$ 58,020
Donations	31,754	33,130	64,884	20,667
Grants	446,100	1,964,270	2,410,370	1,928,546
Special event income	147,782	-	147,782	161,186
Travel and other reimbursement	18,828	18,750	37,578	9,823
Interest and dividend income	9,237	43,131	52,368	21,693
	689,809	2,059,281	2,749,090	2,199,935
Net assets released from restrictions	1,409,885	(1,409,885)	-	-
<b>TOTAL REVENUE AND SUPPORT</b>	<b>2,099,694</b>	<b>649,396</b>	<b>2,749,090</b>	<b>2,199,935</b>
<b>Expenses</b>				
<b>Program Services</b>				
Antiretroviral Project	68,067	-	68,087	101,096
Federal Policy Project	61,325	-	61,325	39,430
Michael Palm HIV Pathogenesis & Prevention Project	182,491	-	182,491	162,368
Hepatitis/HIV Project	163,800	-	163,800	103,830
TB/HIV Advocacy Project	1,026,610	-	1,026,610	450,670
U.S. & Global Community Education & Mobilization	7,819	-	7,819	20,117
TAG Publications and Website	92,373	-	92,373	64,458
<b>TOTAL PROGRAM EXPENSES</b>	<b>1,602,485</b>	<b>-</b>	<b>1,602,485</b>	<b>941,969</b>
Management and general	84,659	-	84,659	67,140
Fundraising	61,654	-	61,654	99,886
<b>TOTAL SERVICES EXPENSES</b>	<b>1,748,798</b>	<b>-</b>	<b>1,748,798</b>	<b>1,108,995</b>
Increase in net assets	350,896	649,396	1,000,292	1,090,140
Net assets, beginning of year	367,238	1,427,004	1,794,242	703,302
<b>NET ASSETS, END OF YEAR</b>	<b>718,134</b>	<b>2,076,400</b>	<b>2,794,534</b>	<b>1,794,242</b>